SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2024, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 67,950 shares of common stock to six (6) new employees under the Company's 20 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 61-1547851 (State o ...

Exhibit 99.1 Kura Oncology Reports First Quarter 2024 Financial Results – Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data for ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – First patient dosed with KO-2806 and cabozantinib in renal cell carcinoma – – $527 million in cash, cash equivalents and investments provide runway into 2027 – – ...

– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1- mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical- stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, ziftomenib, has been g ...

Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Pete De Spain - Executive Vice President of Investor Relations Troy Wilson - President & CEO Tom Doyle - SVP of Finance & Accounting Conference Call Participants Jonathan Chang - Leerink Partners Jason Zemansky - Bank of America Li Watsek - Cantor Fitzgerald Peter Lawson - Barclays Justin Zelin - BTIG Reni Benjamin - Citizens JMP Brad Canino - Stifel Eva Privitera - TD Cowen Operator Good aft ...

业绩总结 - 公司目标是提供长期持久缓解机会，特别是针对急性白血病[5] - 公司拥有Menin抑制剂项目(Ziftomenib)，有望通过单药和组合治疗解决高达50%的急性白血病病例[5] - Tipifarnib和KO-2806等Farnesyl转移酶抑制剂项目显示出持久的疗效[5] - 公司获得来自Bristol Myers Squibb的2,500万美元战略股权投资[5] - 公司现金储备高达5.7亿美元，可支持公司运营至2027年[5] 产品和技术研发 - Ziftomenib在急性白血病治疗中展现出潜在的核心作用[10] - Ziftomenib针对Menin-KMT2A途径，是急性白血病的基础靶点[11] - Ziftomenib在NPM1-m相位1a + 1b患者中表现出高度差异化的单药活性，CR率为40%[16] - Ziftomenib在KMT2A-r相位1a + 1b患者中的CR率为11.1%，MRD阴性率为100%[16] 市场扩张和并购 - Ziftomenib在AML和其他领域具有数十亿美元的潜在机会[32] 其他新策略和有价值的信息 - 公司领导团队和董事会经验丰富[6][7] - Ziftomenib单药治疗在KOMET-001临床试验中表现出鼓舞人心的安全性和耐受性[19] - Tipifarnib在HRAS突变HNSCC患者中显示出临床益处[36] - KO-2806与Cabozantinib在ccRCC模型中展示出协同作用[41]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37620 KURA ONCOLOGY, INC. (Exact name of Registrant as specified in its Charter) Delaware 61-1547851 (State or other jurisdiction of ...

Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Pete De Spain - Head of Investor Relations Troy Wilson - President & Chief Executive Officer Tom Doyle - Senior Vice President of Finance & Accounting Conference Call Participants Jason Zemansky - Bank of America Peter Lawson - Barclays Roger Song - Jefferies Li Watsek - Cantor Fitzgerald Jeet Mukherjee - BTIG Phil Nadeau - TD Cowen Brad Canino - Stifel Operator Good afternoon, ladies and gent ...

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Cor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 61-1547851 (Sta ...